For example, inclisiran can inhibit the synthesis of protein convertase subtilisin-kexin type 9 (PCSK9), thus lowering the level of low-density lipoprotein (LDL) and helping people with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk-equivalents, or heterozygous familial hypercholesterolemia (HeFH). This evidence concerns the gene PCSK9 and familial hypercholesterolemia.